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Effect of Enteric Coating on Antiplatelet Activity
of Low-Dose Aspirin in Healthy Volunteers
Dermot Cox, BSc, PhD; Andrew O. Maree, MSc, MD; Michelle Dooley, BSc; Rona´n Conroy, BA,
Mus B, DSc; Michael F. Byrne, MD; Desmond J. Fitzgerald, MD
Background and Purpose—Aspirin resistance may be relatively common and associated with adverse outcome.
Meta-analysis has clearly shown that 75 mg plain aspirin is the lowest effective dose; however, it is not known whether
the recent increased use of enteric-coated aspirin could account for aspirin resistance. This study was designed to
determine whether enteric-coated aspirin is as effective as plain aspirin in healthy volunteers.
Methods—Seventy-one healthy volunteers were enrolled in 3 separate bioequivalence studies. Using a crossover design,
each volunteer took 2 different aspirin preparations. Five aspirin preparations were evaluated, 3 different enteric-coated
75-mg aspirins, dispersible aspirin 75 mg and asasantin (25-mg standard release aspirin plus 200-mg modified-release
dipyridamole given twice daily). Serum thromboxane (TX) B2 levels and arachidonic acid–induced platelet aggregation
were measured before and after 14 days of treatment.
Results—All other aspirin preparations tested were inferior to dispersible aspirin (P0.001) in their effect on serum TXB2
level. Treatment failure (95% inhibition serum TXB2 formation) occurred in 14 subjects, none of whom were taking
dispersible aspirin. Mean weight for those demonstrating treatment failure was greater than those with complete TXB2
(99%) inhibition (P0.001). Using logistic regression analysis an 80-kg subject had a 20% probability of treatment
failure. Asasantin was the most potent preparation in terms of inhibition of platelet aggregation.
Conclusions—Equivalent doses of the enteric-coated aspirin were not as effective as plain aspirin. Lower bioavailability
of these preparations and poor absorption from the higher pH environment of the small intestine may result in inadequate
platelet inhibition, particularly in heavier subjects. (Stroke. 2006;37:2153-2158.)
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Aspirin (acetylsalicylic acid) is widely used as an antiplateletagent among patients with cardiovascular disease.1 It
inactivates cyclooxygenase (COX), the enzyme responsible for
generation of a potent platelet activator, thromboxane (TX) A2.2
As a consequence, aspirin suppresses TXB2 formation (the stable
metabolite of TXA2) in serum. Aspirin also inhibits platelet
aggregation to arachidonic acid, the substrate for TXA2, and to
weak agonists such as low-dose ADP, but not stronger agonists
like thrombin. Aspirin irreversibly inhibits COX; thus, its effect
on the anucleate platelet, which lacks transcriptional ability, is
prolonged for the lifetime of the cell.3 As a result, complete
suppression of platelet TXA2 formation is possible with chronic
aspirin administration at doses as low as 30 mg daily.4 Because
COX is found in many tissues and especially the stomach, where
inhibition predisposes to gastric ulceration, a strategy of low-
dose aspirin administration is used to target the platelet as unlike
the anucleate platelet other tissues can regenerate COX.5
In contrast to the steep dose-response curve observed with
suppression of platelet TXA2 formation, inhibition of prosta-
cyclin generation in humans increases progressively as aspi-
rin dose exceeds that required for an antiplatelet effect.
Prostacyclin is the major COX product of endothelial cells
and a potent platelet inhibitor. Disruption of the prostacyclin
receptor (IP) in the mouse aggravates the response to vascular
injury attributable in part to the unopposed effects of TXA2.6
The balance between prostacyclin and TXA2 may be equally
important in patients, because selective inhibition of COX-2,
the principal source of prostacyclin in human, has been
associated with an increased risk of myocardial infarction.7,8
Low-dose aspirin is also used to minimize gastrointestinal
injury, which increases progressively as the dose exceeds that
required for an antiplatelet effect.9 The Antithrombotic Tri-
alists’ Collaboration, which analyzed results from a large
number of clinical trials in patients with vascular disease,
concluded that low doses of aspirin, in the range of 75 to 150
mg/d, were as effective as higher doses.1 In an attempt to
further prevent adverse gastric effects, enteric coating is often
used to prevent release of aspirin into the stomach. Thus, 75
mg/d aspirin preparations, many of which today are enteric-
coated, are being prescribed more frequently.10 On average,
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low-dose preparations may achieve the desired effect on the
population; however, drug pharmacokinetics may vary among
individuals. At least 95% inhibition of serum TXB2 formation by
aspirin is required to prevent thromboxane-mediated platelet
activation.11 Here, we compare the ability of 5 low-dose aspirin
preparations to achieve this treatment threshold.
Materials and Methods
Data
The data in this study were drawn from 3 bioequivalence studies,
carried out by our department. Each crossover study compared 2 aspirin
preparations. Table 1 summarizes the preparations and participants.
Drugs
Three different 75-mg enteric-coated aspirin preparations were used:
Nu-Seals (Lilly; enteric 2a and 2b), Caprin (Sinclair Pharmaceuti-
cals; enteric 1) and Protek (Antigen Pharmaceuticals; enteric 3). We
also studied Asasantin Retard (Aggrenox; Boehringer Ingelheim),
which contains 25-mg aspirin in combination with 200-mg modified-
release dipyridamole and is administered twice daily, and 75-mg
dispersible aspirin (Lowasa, Central Laboratories Ltd).
Study Design
Three separate studies were approved by the Irish Medicines Board
and the Ethics Committee of Beaumont Hospital, Dublin. These
studies were designed as regulatory studies for the approval of new
low-dose aspirin preparations. Each study was designed as a bio-
equivalence study using an approved product as the comparator.
Each was performed on healthy volunteers who provided written,
informed consent (see Table 1). Volunteers, aged between 20 and 50
years, were not on medication, had no chronic illnesses and had
normal clinical examinations. A randomized, open-label, cross-over
design was used in each case and the initial treatment was randomly
selected. Volunteers (22 to 25 as determined by European Agency
for the Evaluation of Medicinal Products (EMEA) regulatory re-
quirements, see Table 1) received drug for 14 days, followed by a
14-day wash-out period before administration of the second treat-
ment. Aspirin is an irreversible inhibitor of COX and the mean
platelet lifespan is 10 days12; therefore, a wash-out period of 14 days
was considered adequate to ensure complete elimination of aspirin
before the next treatment arm. Comparison of the pretreatment serum
TXB2 levels from each arm using paired t test showed no significant
difference and thus confirmed the effectiveness of the wash-out.
Blood samples were taken for analysis on the first day predose and
on day 14. In the case of Nu-Seals, Protek and Caprin, 2 tablets were
chewed on the first day. Asasantin tablets were administered twice
daily. Compliance was confirmed by tablet-counting.
Pharmacokinetic studies are not feasible with low-dose aspirin
because the drug is unstable and much of the platelet inhibition occurs
in the presystemic circulation.13 Therefore, bioequivalence analysis was
based on pharmacodynamic measurements. The primary end point of
the study was defined as percentage inhibition of TXB2 on day 14.14
This assay provides an estimate of platelet COX inhibition by aspirin.
We defined 95% inhibition as treatment failure, 95% to 99% inhibi-
tion as incomplete inhibition and 99% inhibition as successful
treatment. A secondary end point was inhibition of arachidonic acid–
induced platelet aggregation.
Serum TXB2
Whole blood was collected in nonsiliconized glass tubes and allowed
to clot at 37°C for 1 hour. The tubes were centrifuged at 900g for 5
minutes and the serum removed and stored at 80°C. For analysis,
samples were thawed, diluted 1 in 500 and assayed by ELISA according
to the manufacturers instructions (R&D Systems).
Platelet Aggregation
Whole blood was collected into 3.8% sodium citrate and centrifuged
at 190g for 2 minutes. The platelet-rich plasma was removed and the
remaining blood centrifuged at 900g for 2 minutes to obtain
platelet-poor plasma. Platelet aggregation studies were performed by
optical aggregometry in a platelet aggregometer (PAP-4, BioData)
using arachidonic acid (1.5 mmol/L; BioData).
Statistical Analysis
Data were initially analyzed by ANOVA (nonparametric Kruskal-
Wallis test). Subsequently, binomial regression (Stata Release 8) was
used to model predictors of outcome. Binomial regression is a special-
ized case of the generalized linear model family. It differs from logistic
regression in using a log-link function rather than the logistic-link
function. Its advantage is that the model estimates the risk ratio, rather
than the odds ratio, making interpretation of the results more intuitive.
However, unlike logistic regression models, binomial regression models
with the log-link function may fail to converge, and, where this
occurred, the relationship was instead modeled using logistic regression
and the effect reported as an odds ratio.
Comparisons of TXB2 values between different aspirin prepara-
tions was performed after log-transforming TXB2 values, resulting in
a good fit to the normal distribution. In the case of study 3 (aspirin
versus asasantin) the TXB2 assay used was unable to detect values of
1 ng/mL. Regression models were therefore based on interval
regression, implemented in Stata’s –intreg- procedure, to account for
the censoring of values introduced.
The clustering of values attributable to repeated measurements on
the same patients was dealt with by using Huber-White robust
variance estimates. Regression dummy terms for each preparation
were used to compare preparations individually with dispersible
aspirin. Wald post hoc tests were used to compare preparations with
each other.
Results
Treatment Effectiveness
The mean serum TXB2 levels differed significantly between
each treatment group (ANOVA; P0.001; see Figure 1). To
further investigate the differences, the 2 Nu-Seals studies
were pooled (enteric 2) and all of the preparations were
compared with dispersible aspirin using interval regression.
Dispersible aspirin (Geometric mean 0.28 ng/mL, 95% CI:
0.091 to 0.87) was more potent than any other preparation
(P0.001). enteric 2 (2.75 ng/mL, 95% CI: 2.09 to 3.63) was
more effective than enteric 3 (5.50 ng/mL, 95% CI: 3.72 to
7.94; P0.0016) and similar to enteric 1 (2.24 ng/mL, 95%
CI: 1.62 to 3.09) and asasantin (1.86 ng/mL, 95% CI: 1.07 to
3.24). Nu-Seals were administered to 2 separate groups and
produced very similar effects on thromboxane levels (4.9
ng/mL, 95% CI: 1.7 to 8.1 and 4.1 ng/mL, 95% CI: 2.4 to 5.8,
TABLE 1. Profile of Volunteers in the 3 Studies Showing meanSD
Study Drug Comparator n Age Weight, kg M/F
1 Caprin (enteric 1) Nu-Seals (enteric 2a) 22 28.25.4 67.510.6 11/11
2 Protek (enteric 3) Nu-Seals (enteric 2b) 24 32.06.9 71.59.8 11/13
3 Asasantin Dispersible aspirin 25 27.74.7 76.217.7 16/9
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P0.7 Mann-Whitney) suggesting that the assay was
reproducible.
Treatment failure (95% inhibition of thromboxane)
did not occur with dispersible aspirin. Asasantin had an 8%
failure rate, and the enteric-coated aspirin preparations had
a 13% failure rate. When all preparations were compared
using a 2 test for their ability to produce either 95% or
95% inhibition of serum thromboxane levels there was a
statistically significant difference (P0.011) between
preparations. Incomplete TXB2 inhibition (99% inhibi-
tion) rose from 8% in the aspirin group to 54.3% among
those on enteric-coated aspirin and inclusion of this in the
2 test was highly significant (P0.0004). The number of
subjects achieving predefined levels of inhibition of serum
TXB2 is compared for the different preparations in Figure
2 and Table 2.
The levels of platelet aggregation induced by arachidonic
acid were compared and aspirin preparations differed signif-
icantly (ANOVA; P0.001; Figure 3). Asaasantin was the
most effective inhibitor (4% aggregation, 95% CI: 2.5 to 5.4)
and enteric 3 was the least effective (12.8% aggregation, 95%
CI: 3.4 to 22).
Effect of Weight
Table 3 shows the effect of weight on risk of treatment failure
for asasantin and enteric-coated aspirin. Weight was signifi-
cantly associated with both risk of treatment failure (95%
inhibition of TXB2) and incomplete TXB2 inhibition (99%).
A 10-kg (22-lb) increase in weight was associated with an
approximate doubling of risk of treatment failure (relative
risk 1.9 [95% CI: 1.3 to 2.7] for asasantin and 2.2 [95% CI:
1.7 to 3.0] for enteric-coated aspirin). The binomial model for
weight as a predictor of incomplete inhibition among partic-
ipants taking asasantin failed to converge, and the effect was
estimated using logistic regression, and therefore Asasantin
data are presented as odds ratios rather than risk ratios. Figure
4 graphically represents the relationship between weight and
treatment outcome for participants taking enteric-coated as-
Aspirin Preparation
Asasantin Aspirin Enteric 1 Enteric 2a Enteric 2b Enteric 3
Th
ro
m
bo
xa
n
e
 B
2 
(ng
/m
l)
0
100
200
300
400
500
600
Aspirin Preparation
Asasantin Aspirin Enteric 1 Enteric 2a Enteric 2b Enteric 3
Th
ro
m
bo
xa
n
e
 
B 2
 
(ng
/m
l)
0
10
20
30
40
A
B
Figure 1. Serum TXB2 levels in (a) volun-
teers before starting aspirin therapy and
(b) 14 days after aspirin therapy. Enteric
2a and 2b are 2 separate studies with
the same product. The horizontal line in
the center of the box represents the 50th
percentile, the ends of the box represent
the 25th and 75th percentiles, the tips of
the whiskers represent the 5th and 95th
percentiles and the closed circles indi-
cate individual outliers.
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pirin. Predicted probability of incomplete treatment response
rose from 40% at 60 kg (132 lb) to 90% at 100 kg (220 lb),
whereas predicted probability of treatment failure rose from
10% at 70 kg (154 lb) to over 50% at 90 kg (198 lb).
Discussion
We performed 3 bioequivalence studies on new low-dose
aspirin preparations according to EMEA requirements. Sur-
prisingly, each study showed that the test product was either
significantly inferior or superior to the comparator. Thus, we
decided to combine all of the studies to determine whether we
could identify factors which determined efficacy of the
different preparations. In particular we addressed the effect of
enteric-coating on aspirin bioavailability.
All aspirin preparations studied produced marked inhibi-
tion of serum TXB2 production that ranged from 96.4%
inhibition for enteric 3 to 99.5% inhibition for plain aspirin.
These results are comparable with a recent study designed to
test the bioavailability of enteric-coated aspirin (81 mg) that
showed 97.4% inhibition of serum thromboxane production
among 12 subjects15 although no comparison with plain
aspirin was performed. There was significant variability in
the levels of inhibition of thromboxane production achieved
with the different preparations with 75-mg dispersible aspirin
producing the highest levels of inhibition with the lowest
variability. These results are consistent with a previous report
of inter- and intrasubject variability in low-dose aspirin
response among healthy volunteers.16 Variability was also
found when 2 enteric-coated preparations of aspirin 500 mg
were compared with uncoated aspirin.17 Studies that focus on
mean inhibition of serum thromboxane generation may over-
look the significant number of patients with lower levels of
inhibition.
All preparations showed strong inhibition of arachidonic
acid–induced platelet aggregation; however, there was signif-
icant variation between preparations. The most effective
preparation was assasantin despite the fact that it delivers the
lowest aspirin dose (50 mg) which may reflect the role of
dipyridamole in the asasantin preparation. Dipyridamole
inhibits platelet aggregation by inhibition of both adenosine
uptake and phosphodiesterase activity.18 Two volunteers
showed sustained platelet aggregation despite treatment for
14 days with Protek. Platelet aggregation assays were re-
peated but remained high. Compliance was confirmed by
direct enquiry, tablet counting and by the high suppression of
thromboxane synthesis. However, these volunteers could not
be classed as aspirin resistant because they showed complete
inhibition of platelet aggregation on the comparator enteric
preparation.
The clinical relevance of incomplete inhibition of platelet
function by aspirin has been evaluated in a number of studies.
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Figure 2. Number of volunteers achieving different levels of
serum TXB2 inhibition for the various aspirin preparations. Data
were analyzed by 2 test.
TABLE 2. Outcome of Treatment With Three Classes of
Preparation
Drug
No. of
Participants
Treatment Failure*
(95% CI)
Incomplete Inhibition**
(95% CI)
Aspirin 25 0% (0%–13.3%) 8% (2.1%–30.5%)
Asasantin 25 8.0% (1.9%–27.7%) 36.0% (21.3%–60.9%)
Enteric-
coated
aspirin
46 13.0% (7.8%–21.0%) 54.3% (44.2%–66.9%)
The results are expressed as percentages and their confidence intervals.
*Treatment failure: 95% inhibition of thromboxane; **incomplete inhibi-
tion: 99% inhibition of thromboxane.
TABLE 3. Relative Risk (*Odds Ratio) of Treatment Failure
(<95% Inhibition) and Incomplete (<99%) Inhibition of
Thromboxane by Asasantin and Enteric-Coated Aspirin for a
10-kg Increase in Body Weight, Calculated by Binomial
Regression or *Logistic Regression
Treatment Failure Incomplete Inhibition
Preparation
Relative Risk
per 10-kg
Weight
Increase 95% CI
Relative Risk
per 10-kg
Weight
Increase 95% CI
Asasantin 1.9 1.3–2.7 4.4* 1.7–11.1*
Enteric-coated
aspirin
2.2 1.7–3.0 1.3 1.2–1.5
Aspirin Preparation
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Figure 3. Arachidonic acid–induced platelet aggregation in vol-
unteers after 14 days of treatment. Enteric 2a and 2b are 2 sep-
arate studies with the same product. The horizontal line in the
center of the box represents the 50th percentile, the ends of the
box represent the 25th and 75th percentiles, the tips of the
whiskers represent the 5th and 95th percentiles and the closed
circles indicate individual outliers.
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Persistent thromboxane production has been associated with
poor outcome,19 and there is also evidence of poorer outcome
in patients defined as aspirin resistant by platelet aggregom-
etry.20 In our study 14 subjects failed to achieve an adequate
treatment response, defined as 95% inhibition of serum
TXB25,11,21 on at least 1 aspirin preparation. In all cases, each
subject showed adequate inhibition on an alternative aspirin
preparation, suggesting that differences were in bioavailabil-
ity rather than drug response. Subjects who failed to achieve
95% inhibition of serum TXB2 were heavier, a finding
which supports a mechanism of reduced bioavailability.
Thus, enteric-coated preparations may deliver a lower dose of
aspirin than equivalent doses of plain aspirin. Reduced aspirin
delivery may be more evident in heavier subjects who have a
larger volume of distribution.
It is not unreasonable to expect a drug to achieve its
intended pharmacological effect, which in the case of aspirin
is inhibition of platelet COX. Thus, aspirin efficacy is best
determined by assays directly dependent on COX function
such as TXB2 generation in serum and arachidonic acid–
induced platelet aggregation. Complete suppression of plate-
let COX and thromboxane formation appears to be necessary
for optimal clinical benefit. Mechanisms of aspirin resistance
may be broadly divided into pharmacokinetic, attributable to
inadequate aspirin absorption and pharmacodynamic, where
insufficient COX inhibition occurs despite normal absorption.
Our study suggests that reduced bioavailability of aspirin
from low-dose, enteric-coated preparations may explain some
cases of aspirin resistance (pharmacokinetic resistance). As-
pirin is deacetylated to inactive salicylate at a number of sites,
including the gut; thus, its bioavailability is about 50%.13
Plain aspirin is absorbed from the stomach, where the low pH
protects aspirin against deacetylation and maintains aspirin in
a nonionized form which encourages absorption. In contrast,
enteric-coated preparations release aspirin into the upper
small intestine, which has a near-neutral pH, and therefore
more of the aspirin may be inactivated. Also enteric prepa-
rations may differ in their rate of dissolution at the intestinal
pH (pH 6). Consequently, the dose of aspirin delivered to the
circulation (bioavailability) may be less for enteric-coated
preparations.
The above referenced secondary prevention studies suggest
that aspirin resistance is common among patients with cardio-
vascular disease including those who received higher doses of
aspirin. Our data, based on healthy volunteers, demonstrated no
case of pharmacodynamic resistance and supports a pharmaco-
kinetic mechanism for suboptimal aspirin response. Therefore,
in addition to reduced bioavailability, other factors may deter-
mine aspirin response in patients with cardiovascular disease.22
Generation of aspirin-insensitive thromboxane has been demon-
strated in patients with unstable angina and is thought to be
attributable to the formation of thromboxane or a precursor in
cells other than the platelet. Peroxidation of arachidonic acid
may lead to enhanced formation of aspirin-insensitive isopros-
tanes and platelet activation23 or COX-2–mediated production of
thromboxane by circulating monocytes may occur.24
There is no doubt that our study was performed in a
different population (healthy volunteers) to the target patient
population. However, in a recent study of stable cardiovas-
cular patients on enteric-coated aspirin we also found a
weight-dependent effect of aspirin on the suppression of
TXA2.25 Compliance is also an issue; however, our popula-
tion was hospital staff and tablet counting was used to check
compliance. If anything, compliance would be higher than in
a patient group.26 If stable plasma levels of drug cannot be
obtained in highly motivated healthy volunteers under close
scrutiny it is unlikely to be achieved in patients on multiple
medications who have coexisting pathology which predis-
poses to aspirin resistance.27
Increasingly, lower doses of aspirin are being used in an
effort to avoid adverse effects and preserve prostacyclin
formation.1 However, current aspirin doses are reaching the
limit of efficacy and in some instances low-dose aspirin is
no-dose aspirin. Current American Heart Association guide-
lines recommend the use of 75 to 160 mg aspirin daily for
primary prevention of stroke and myocardial infarction.28 Our
data would suggest that patients who use low-dose enteric-
coated aspirin preparations are less likely to attain full benefit
of aspirin because enteric-coated preparations deliver a dose
equivalent to 50 mg plain aspirin. The use of a higher dose of
aspirin would solve the problem; however, this leads to
increased bleeding events.29 Evidence for increased gastroin-
testinal bleeding with low-dose plain aspirin relative to
equivalent dose enteric-coated preparations is unconvincing,
and therefore perhaps reversion to the original drug prepara-
tion, if tolerated, may be the best strategy. In conclusion, the
use of enteric-coated 75-mg aspirin preparations in heavier
individuals may predispose to incomplete inhibition of COX
compared with plain aspirin (75 mg). To ensure adequate
inhibition of thromboxane production plain (75 mg) aspirin or
a bioequivalent dose of enteric aspirin (estimated to be
around 100 mg) should be used.
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